Tevogen shares skyrocket as it projects $1B in revenue for its oncology pipeline

 

• Tevogen (TVGN), on Monday, reaffirmed its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. 
• The company also said that it has recently executed an agreement with CD 8 Technology Services providing up to $50 million for the company’s dedicated R&D and manufacturing facility; no impact on shareholder equity.
• Tevogen (TVGN) shares were up more than 46% in extended trading. 

https://www.msn.com/en-us/money/companies/tevogen-shares-skyrocket-as-it-projects-1b-in-revenue-for-its-oncology-pipeline/ar-AA1DN0q6